Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis

To cite this article: Kim YH, Yang TY, Park C‐S, Ahn S‐H, Son BK, Kim JH, Lim DH, Jang TY. Anti‐IL‐33 antibody has a therapeutic effect in a murine model of allergic rhinitis. Allergy 2012; 67: 183–190. Background:  Interleukin (IL)‐33 is involved in the Th2 immune response and could play an essenti...

Full description

Saved in:
Bibliographic Details
Published inAllergy (Copenhagen) Vol. 67; no. 2; pp. 183 - 190
Main Authors Kim, Y. H., Yang, T. Y., Park, C.-S., Ahn, S.-H., Son, B. K., Kim, J. H., Lim, D. H., Jang, T. Y.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.02.2012
Blackwell
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:To cite this article: Kim YH, Yang TY, Park C‐S, Ahn S‐H, Son BK, Kim JH, Lim DH, Jang TY. Anti‐IL‐33 antibody has a therapeutic effect in a murine model of allergic rhinitis. Allergy 2012; 67: 183–190. Background:  Interleukin (IL)‐33 is involved in the Th2 immune response and could play an essential role in nasal allergy. Therefore, we aimed to investigate the therapeutic potential of anti‐IL‐33 for allergic rhinitis (AR). Methods:  Twenty‐four BALB/c mice were used. In group A (control group, n = 6), mice were sensitized and challenged with saline. Group B [ovalbumin (OVA) group, n = 6] mice received intraperitoneal and intranasal OVA challenge. In group C (control IgG group, n = 6), mice were injected intraperitoneally with rabbit control IgG before OVA challenge. In group D (anti‐IL‐33 group, n = 6), anti‐IL‐33 was injected before challenge. We evaluated the number of nose‐scratching events and external morphology; serum total and OVA‐specific IgE; number of eosinophils, neutrophils, and lymphocytes in bronchoalveolar lavage (BAL) fluid; histopathologic examination of nasal cavity; and IL‐4, IL‐5, and IL‐13 in BAL fluid. Results:  Anti‐IL‐33 treatment significantly reduced the nose‐scratching events and ameliorated skin denudation. Serum total and OVA‐specific IgE was significantly decreased in group D. The number of eosinophils in BAL fluid was also significantly decreased. Eosinophilic infiltration in the nasal cavity was significantly decreased in group D. IL‐4, IL‐5, and IL‐13 in BAL fluid were also significantly decreased after treatment. Conclusions:  Anti‐IL‐33 antibody has a therapeutic potential for experimental AR.
Bibliography:ark:/67375/WNG-WHQLGJDG-W
istex:1EF826EA10943B4DB6D6C2EEAD46B710DD760936
ArticleID:ALL2735
Dae Hyun Lim and Tae Young Jang are equally responsible for this work.
Edited by: Hans‐Uwe Simon
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0105-4538
1398-9995
1398-9995
DOI:10.1111/j.1398-9995.2011.02735.x